Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression

Investigational New Drugs

Volumn 23, Issue 1, 2005, Pages 3-9

  Medina Gundrum, Leticia ^a   Cerna, Cesario ^a   Gomez, Lionel ^a   Izbicka, Elzbieta ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

cloning; HMN 176; HMN214; stem cell assay

Indexed keywords

4 [2 [2 [N (4 METHOXYBENZENESULFONYL)AMINO]PHENYL]ETHENYL]PYRIDINE 1 OXIDE; ANTINEOPLASTIC AGENT; CISPLATIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUOROURACIL; HMN 176; PYRIDINE 1 OXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TISSUE; CLONING; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS RESISTANCE; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; EX VIVO STUDY; EXPOSURE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UPREGULATION;

ANTINEOPLASTIC AGENTS; BENZYLIDENE COMPOUNDS; COLONY-FORMING UNITS ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRIDINES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 8644285456     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000047100.64540.f6     Document Type: Article

References (20)

1. Takagi M, Honmura T, Watanabe S, Yamaguchi R, Nogawa M, Nishimura I, Katoh F, Matsuda M, Hidaka H: In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs 21(4): 387-399, 2003
2. Tanaka H, Ohshima N, Ikenoya M, Komori K, Katoh F, Hidaka H: HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug resistant cells by targeting the transcription factor NF-Y. Cancer Res. 63(20): 6942-6947, 2003
3. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461-463, 1977
4. Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R: Association between human tumor colony forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 70: 1027-1041, 1981
5. Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker RH, Von Hoff DD: Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 70: 1379-1382, 1986
6. Hanauske U, Hanauske A-R, Marshall MH, Muggia VA, Von Hoff DD: Biphasic effects of vanadium salts on in vitro tumor colony growth. Int J Cell Cloning 5: 171-178, 1987
7. Von Hoff DD, Clark GM, Stogdill BJ, Sarodsy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AP, Sandbach JE: Prospective clinical trial of a human tumor cloning system. Cancer Res 43: 1926-1931, 1983
8. Shoemaker RH, Wolpert-Defillipes MK, Kern DH, Lieber MM, Makuch RW, Melnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM, Von Hoff DD: Application of a human tumor colony-forming assay to new drug screening. Cancer Res 45: 2145-2153, 1985
9. Browman GP, Levine MN, Robert RS: Editorial: Bench to bedside research and the human tumor stem-cell assay - bridging the credibility gap. J Clin Oncol 4: 1730-1731, 1986
10. Von Hoff DD: Human tumor stem cell assays. Int J Cell Cloning 5: 365-367, 1987
11. Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD: Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs 3: 121-124, 1992
12. Eckardt JR, Burris III HA, Kuhn JG, Bissery MC, Klink-Alakl M, Clark GM, Von Hoff DD: Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 86 (1): 30-33, 1994
13. Raymond E, Hanauske A, Faivre S, Izbicka E, Clark G, Rowinsky EK, Von Hoff DD: Effects of prolonged versus short-term exposure paclitaxel (Taxol®) on human tumor colony-forming units. Anti-Cancer Drugs 8: 379-385, 1997
14. Hidalgo M, Izbicka E, Cerna C, Gomez L, Rowinsky EK, Weitman SD, Von Hoff DD: Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay. Anti-Cancer Drugs 10(3): 295-302, 1999
15. Diab SG, Hilsenbeck SG, Izbicka E, Weitman SD, Von Hoff DD: Significant activity of a novel cytotoxic agent, Ly295501, against a wide range of tumors in the human tumor cloning system. Anti-Cancer Drugs 10: 303-307, 1999
16. Petit T, Izbicka E, Lawrence RA, Bishop WR, Weitman SD, Von Hoff DD: Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Ann Oncol 10: 449-153, 1999
17. Sakata K, Shigemasa K, Nagai N, Ohama K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17(4): 673-681, 2000
18. Von Hoff, Daniel D: He's Not Going to Talk About In Vitro Predictive Assays Again, Is He? JNCI 82(2): 96-101, 1990
19. Li YT, Shen F, Bai JY, Cheng GF: Inhibition of dexamethasone, indomethacin and resveratrol on matrix metalloproteinase-9 and the mechanism of inhibition. Yao Xue Xue Bao 38(7): 501-504, 2003
20. Liang Y, McDonnell S, Clynes M. Examining the relationship between cancer invasion/metastasis and drug resistance. Curr Cancer Drug Targets 2(3): 257-277, 2002